Raynier Devillier

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

32h-index3.2kcitations216works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(131), Acute Myeloid Leukemia Research(83), Acute Lymphoblastic Leukemia research(44), Chronic Myeloid Leukemia Treatments(31), Immune Cell Function and Interaction(30)

Publications216 total

Supplementary Tables S1-S4 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS<sup>+</sup> CD4<sup>+</sup> T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
2025Open Access
Supplementary Figures S1-S8 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS<sup>+</sup> CD4<sup>+</sup> T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
2025Open Access
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT
Bone Marrow Transplantation·2025
Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study
Blood·2025Open Access
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC
Bone Marrow Transplantation·2025
Allogeneic hematopoietic stem cell transplantation in patients with germ line <i>DDX41</i> mutated myeloid malignancies
Blood Advances·2025Open Access
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study
Blood Cancer Journal·2025Open Access
Intermediate-Dose Cytarabine as Postinduction AML Therapy
NEJM Evidence·2025· 5 cited
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (<scp>SFGM</scp>‐<scp>TC</scp>)
American Journal of Hematology·2025· 1 citedOpen Access
Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An <scp>IPC</scp>‐<scp>DATAML</scp>‐<scp>MSKCC</scp> Retrospective Study
American Journal of Hematology·2025· 1 citedOpen Access
Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
Blood·2024Open Access
SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II
Blood·2024· 1 citedOpen Access
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-<i>Versus</i>-Host Disease : Results from Early Access Program in Europe
Blood·2024· 1 citedOpen Access
Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics
European Journal Of Haematology·2024Open Access
CD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML.
2024Open Access
PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Haematologica·2024· 2 citedOpen Access
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
American Journal of Hematology·2024· 4 citedOpen Access
1087: TBI-based conditioning regimen vs chemotherapy prior to transplant in ALL. A study from the SFGM-TC.
Radiotherapy and Oncology·2024
Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
Bone Marrow Transplantation·2024· 1 cited
Durable engraftment after pharmacological pre-transplant immune suppression followed by reduced-toxicity myeloablative haploidentical stem cell transplantation in highly HLA-immunized adults with sickle cell disease
Bone Marrow Transplantation·2024· 3 cited
page 1 of 11Next →

Frequent Co-authors

Didier Blaise(37), Luca Castagna(25), Christian Chabannon(24), Norbert Vey(22), Angéla Granata(20), Samia Harbi(18), Sabine Fürst(17), Catherine Faucher(14), Boris Calmels(14), Stéfania Bramanti(13), Réda Bouabdallah(12), Jean El Cheikh(11), Thomas Pagliardini(10), Claude Lemarié(10), Roberto Crocchiolo(9), Valério Maisano(8), Barbara Sarina(8), Faézeh Legrand(8), Pierre‐Jean Weiller(8), Daniel Olive(7)